GENFLEET-B (02595) saw its shares rise nearly 6% during the trading session. At the time of writing, the stock was up 4.41%, trading at HK$45.94, with a turnover of HK$21.2173 million.

GENFLEET announced that preclinical research data for its self-developed oral Pan-RAS (ON) inhibitor, GFH276, was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21 local time. The poster demonstrated that in various animal models with RAS mutations, GFH276 achieved or surpassed the tumor suppression effect of RMC-6236 at doses as low as one-third.

Furthermore, in animal studies combining GFH276 with cetuximab, chemotherapeutic agents, or PD-1 inhibitors, the drug showed significant synergistic tumor suppression effects and extended progression-free survival. It is reported that GFH276 is the third Pan-RAS inhibitor globally to enter clinical trials, and early clinical data have shown preliminary results consistent with preclinical efficacy and safety profiles.